Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Mycobacterium tuberculosis and the response of its host
-
2. The pathogenesis of tuberculosis
- Dr. William R. Bishai
-
3. Immune response and rational development of vaccines and biomarkers
- Prof. Dr. Stefan H. E. Kaufmann
-
4. Molecular mechanisms of drug resistance in M. tuberculosis
- Dr. Daniela Cirillo
- The epidemiology of tuberculosis
-
5. The basic epidemiology of tuberculosis (TB)
- Dr. David Dowdy
-
6. Global epidemiology of TB
- Dr. Philippe Glaziou
-
7. Social determinants of tuberculosis
- Dr. Knut Lönnroth
- The control of tuberculosis
-
8. Treatment of tuberculosis
- Dr. Jean-Pierre Zellweger
-
9. The End TB Strategy towards TB elimination 1
- Dr. Mario Raviglione
-
10. The End TB Strategy towards TB elimination 2
- Dr. Mario Raviglione
-
11. Financing TB care and control
- Dr. Christopher Fitzpatrick
- Dr. Andrea Pantoja
-
12. Tuberculosis and COVID-19
- Prof. Giovanni Battista Migliori
-
13. Multidrug resistant tuberculosis (MDR-TB): an update
- Dr. Simon Tiberi
-
14. Impact of HIV on tuberculosis in the developing world and how to manage it
- Prof. Anthony D. Harries
-
16. TB in children
- Prof. Ben J. Marais
-
17. Community engagement in tuberculosis care
- Ms. Lana Syed
-
18. India: the epicentre of global TB control
- Dr. Madhukar Pai
-
19. Community engagement in TB care
- Dr. Haileyesus Getahun
- Research and development for new approaches in the control of tuberculosis
-
20. Development of new regimens for tuberculosis
- Dr. Zhenkun Ma
-
22. Pharmacometrics in tuberculosis
- Prof. Charles A. Peloquin
-
23. Extrapulmonary tuberculosis
- Dr. Scott Heysell
-
24. The role of surgery in tuberculosis management
- Dr. Richard Zaleskis
- Archived Lectures *These may not cover the latest advances in the field
-
25. The development of current treatments for tuberculosis
- Dr. Andrew Nunn
-
26. The pathogenesis of tuberculosis
- Dr. William R. Bishai
-
27. Basics of tuberculosis epidemiology
- Prof. Frank Cobelens
-
29. The international approach to the control of tuberculosis
- Dr. Mario Raviglione
-
30. Public-private mix for TB care and control
- Dr. Mukund Uplekar
Printable Handouts
Navigable Slide Index
- Introduction
- Tuberculosis global statistics in 2019
- Outline - forms of human TB
- Mycobacterium tuberculosis (M. tb)
- Mycobacterium tuberculosis infection
- Phases of M. tb infection in humans
- The spectrum of TB: from infection to active disease
- Outline - virulence factors within macrophages
- M. tb virulence factors
- Immune subversion strategies and host defense
- Signaling through M. tb cyclic-dinucleotides
- Recognition of M. tb RNA by RIG-I & MDA-5
- The SecA2 secretion system is needed
- Outline: tissue-mediated pathogenesis
- Phases of immune response to M. tb
- Granuloma evolution and cellular composition of the necrotic granuloma
- Lung cavitation, hallmark of advanced TB
- How does necrosis occur?
- Study of necrotizing lesions in B6.Sst1s mice
- Integrated stress response (ISR) mediates necrosis
- Effect of ISR inhibitor on tuberculosis progression
- Outline - TB pathogenesis during HIV co-infection
- HIV and M. tb co-infection
- Proposed mechanism of HIV-induced reactivation of latent TB
- HIV causes different changes within M. tb
- Thank you
Topics Covered
- Forms of human TB
- Mycobacterium tuberculosis (M. tb)
- Virulence factors within macrophages
- Immune subversion strategies and host defense
- Tissue-mediated pathogenesis
- Phases of immune response to M. tb
- Granuloma evolution and cellular composition of the necrotic granuloma
- TB pathogenesis during HIV co-infection
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Bishai, W.R. (2021, November 28). The pathogenesis of tuberculosis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 30, 2024, from https://doi.org/10.69645/KMJG7455.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Bishai hold patents related to recombinant BCG strains with potential use as TB vaccines.
A selection of talks on Infectious Diseases
Transcript
Please wait while the transcript is being prepared...
0:00
Welcome, my name is Bill Bishai.
I'm a professor at Johns Hopkins University, in Baltimore, Maryland.
My topic today is the pathogenesis of tuberculosis.
I'd like to share a little bit of epidemiology about tuberculosis in the world,
then take you through four topics on the pathogenesis of tuberculosis.
0:23
Epidemiologically, tuberculosis is one of the most lethal diseases on the planet.
The statistics from 2019 revealed that there were 10 million new cases of tuberculosis
globally, and about 200,000 cases of multi-drug-resistant tuberculosis.
Within these cases, there were 1.4 million deaths.
Tuberculosis is the leading cause of death in patients with HIV.
0:51
The outline I'd like to address with you today is shown on this slide.
First, I'd like to address the forms of human tuberculosis.
Second, I'd like to address virulence factors of the microbe, within macrophages.
Third, I'd like to address the important topic of the tissue-mediated pathogenesis
of M. tuberculosis, specifically addressing how the bacterium leads to the formation
of granulomas, which are the classic lesions seen in humans.
Lastly, I'd like to discuss the important topic of TB pathogenesis during HIV co-infection.
1:29
The microbe is Mycobacterium tuberculosis.
It's an obligate aerobic, facultative intracellular bacterium.
One-quarter of the world's population is estimated to be latently infected with this microbe.
Importantly, M. tuberculosis can persist in humans for decades, before reactivating
to cause active post-primary tuberculosis disease.
During this persistent phase, it's called latent tuberculosis infection.